VJOncology is committed to improving our service to you

ASCO 2020 | Repurposing irinotecan

VJOncology is committed to improving our service to you

Sunandana Chandra

Sunandana Chandra, MD, MS, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, discusses a couple of abstracts presented at ASCO 2020 around repurposing irinotecan. These included the Phase I study of rucaparib and irinotecan in advanced solid tumors with homologous recombination deficiency mutations, and another Phase I study looking at the use of Pen-866, a miniature drug conjugate of a heat shock protein 90 ligand linked to SN38 for patients with advanced solid malignancies. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter